Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

03/28/2012 | 09:54am US/Eastern

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

React to this article
Latest news on ALLERGAN, INC.
08/26 ALLERGAN : Assigned Patent
08/24 ALLERGAN : Issues Voluntary Nationwide Recall In The U.S. Of Specific Lots Of RE..
08/24 ALLERGAN : Issues Voluntary Nationwide Recall in the U.S. of Specific Lots of RE..
08/19 ALLERGAN : Assigned Patent
08/18 Teva likely to oppose Mylan's bid to take over Perrigo
08/15 ALLERGAN : Completes Oculeve Acquisition
08/13 ALLERGAN : Finalizes Oculeve Acquisition
08/12 ALLERGAN : is earning bridge for Teva (Goldman Sachs)
08/12 IRONWOOD PHARMACEUTICALS : and Allergan Enter Agreement to Co-Promote VIBERZI fo..
08/10 ALLERGAN : New Podcast on Non-Surgical Facelift Featuring Chattanooga Aesthetics..
Advertisement
Income Statement Evolution
More Financials